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Abstract
IMPORTANCE Early plasma transfusion for womenwith severe postpartum hemorrhage (PPH) is
recommended to prevent coagulopathy. However, there is no comparative, quantitative evidence on
the association of early plasma transfusion with maternal outcomes.
OBJECTIVE To compare the incidence of adverse maternal outcomes among womenwho received
plasma during the first 60 minutes of persistent PPH vs women who did not receive plasma for
similarly severe persistent PPH.
DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study used a consecutive sample
of women with persistent PPH, defined as PPH refractory to first-line measures to control bleeding,
between January 1, 2011, and January 1, 2013. Time-dependent propensity scorematchingwas used
to select women who received plasma during the first 60minutes of persistent PPH andmatch each
of themwith a womanwho had shown the same severity and received the same treatment of PPH
but who had not received plasma at the moment of matching. Transfusions were not guided by
coagulation tests. Statistical analysis was performed from June 2018 to June 2019.
EXPOSURES Transfusion of plasma during the first 60minutes of persistent PPH vs no or later
plasma transfusion.
MAINOUTCOMES ANDMEASURES Incidence of adversematernal outcomes, defined as a
composite of death, hysterectomy, or arterial embolization.
RESULTS This study included 1216 women (mean [SD] age, 31.6 [5.0] years) with persistent PPH, of
whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. Seven
women (0.6%) died because of PPH, 62 women (5.1%) had a hysterectomy, and 159 women (13.1%)
had arterial embolizations. Among women who received plasma during the first 60 minutes of
persistent PPH, 114 women could bematched with a comparable womanwho had not received
plasma at themoment of matching. The incidence of adverse maternal outcomes was similar
between the women, with adverse outcomes recorded in 24 women (21.2%) who received early
plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio,
1.09; 95% CI, 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.
CONCLUSIONS AND RELEVANCE In this cohort study, initiation of plasma transfusion during the
first 60 minutes of persistent PPH was not associated with adverse maternal outcomes compared
with no or later plasma transfusion, independent of severity of PPH.
JAMA Network Open. 2019;2(11):e1915628. doi:10.1001/jamanetworkopen.2019.15628
Key Points
Question Is plasma transfusion within
the first 60 minutes of persistent
postpartum hemorrhage (PPH)
associated with incidence of maternal
adverse outcomes?
Findings In this cohort study of 114
propensity score–matched womenwith
persistent PPH, plasma transfusion
within the first 60minutes of persistent
PPHwas not associatedwith incidence
of maternal adverse outcomes
compared with no or later plasma
transfusion, independent of severity of
PPH at the time of plasma transfusion.
Meaning These findings do not support
the theory that early plasma transfusion
inwomenwith persistent PPH is better
than no or later plasma transfusion.
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Author affiliations and article information are
listed at the end of this article.
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Introduction
Obstetric hemorrhage accounts for 27% of all maternal deaths.1 In high-resource settings, maternal
death due to postpartum hemorrhage (PPH) has become uncommon, but PPH remains an important
cause of severe maternal morbidity.2-7
Womenwith persistent PPH are at risk of developing coagulopathy due to depletion of
coagulation factors and platelets.8-12 Coagulopathy can eventually lead to worse maternal outcomes.
Timely transfusion of plasmamay prevent coagulopathy and thereby improvematernal outcomes.
Results from a 2015 study13 among patients with trauma suggest that formulaic plasma
transfusion, comprising a fixed ratio of plasma to red blood cells (RBCs), is associated with better
outcomes. Whether such transfusion strategies are also associated with better outcomes among
womenwith persistent PPH is not clear. Some studies have suggested that early and aggressive
plasma transfusion has a positive association with outcomes in womenwith PPH.14-19 However, a
2017 study20 suggested that womenwith persistent PPH have better outcomes when plasma
transfusion is postponed or even avoided. Uncertainty about the outcomes associated with plasma
transfusion among women with persistent PPH can lead to significant variation in clinical practice.
This variation in practice, along with careful documentation of confounding factors, enables the use
of routinely collected clinical data to compare outcomes among women treated according to
different treatment strategies.
The aim of this study was to assess whether early plasma transfusion is associated with
improved maternal outcomes in women with persistent PPH. Our hypothesis was that initiation of
plasma transfusion during the first 60 minutes of persistent PPH would be associated with fewer
adverse maternal outcomes, defined as maternal death, hysterectomy, or arterial embolization
compared with womenwho received no or later plasma transfusion.
Methods
Approval was obtained from theMedical Ethics Research Committee of the Leiden University
Medical Center and from the institutional review board of each study center, and a waiver of
informed consent was granted because the study used deidentified data. The study was registered
in the Netherlands Trial Register21 and reported according to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline.
StudyDesign and Population
The transfusion strategies in women during major obstetric hemorrhage (TeMpOH-1) study21 was a
multicenter, retrospective cohort study in the Netherlands that included consecutive women who
had received 4 or more units of RBCs or a multicomponent blood transfusion within 24 hours after
giving birth because of severe PPH (ie,1000mL blood loss) from January 1, 2011, to January 1,
2013. Amulticomponent blood transfusion was defined as transfusion of at least 1 unit of packed
RBCs in combination with plasma or platelet concentrates. We selected women from transfusion
databases and birth registries in 61 participating hospitals.
From this cohort, we identified womenwith persistent PPH, defined as PPHwith at least 1000
mL of blood loss refractory to first-line interventions to control bleeding.8,22 First-line interventions
depended on the cause of bleeding, as previously described (eTable 1 in the Supplement).23 We
regarded the time of initiation of the first-line intervention to stop PPH as themoment of diagnosis
of persistent PPH, under the assumption that refractoriness to first-line treatment would become
evident shortly after initiation of this therapy. Women were followed up from onset until cessation
of PPH.
We excluded womenwith unknown timing of initiation of plasma transfusion. We also excluded
womenwith initiation of plasma transfusion for any reason other than correcting coagulopathy
secondary to PPH (ie, comorbidity).
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Data Collection
Trainedmedical students and research nurses uniformly performed comprehensive health record
reviews. From routinely collectedmedical information, we reconstructed the treatment course of
every womanwith PPH.We checked all data for completeness and inconsistencies and repeated
on-site health record review as necessary. Data included comorbidity; mode of birth; primary cause
of hemorrhage; consecutive estimates of blood loss and time of estimations; blood pressure, heart
rate, and time of measurements; volume of crystalloids and colloids for fluid resuscitation; time of
transfusions of packed RBCs, plasma, and platelets; and time of obstetric, radiological, and
hemostatic interventions to stop bleeding.
Fresh Frozen Plasma Transfusion
Womenwith plasma transfusions received 1 or more units of fresh frozen plasma during the
treatment of persistent PPH. Transfusion of plasma was not guided by coagulation tests. The time to
plasma transfusion was defined as the interval between themoment of diagnosis of persistent PPH
and administration of the first unit of plasma.
Previous studies on hemostatic interventions to treat coagulopathy in pregnant and
nonpregnant patients with major hemorrhage showed beneficial associations of these interventions
when initiated early after the start of hemorrhage, specifically within 3 hours.24,25 Therefore, we
examined the association of plasma transfusion during the first 60minutes of persistent PPH with
maternal outcomes.
Outcome
The outcomewas the incidence of adverse maternal outcomes, defined as a composite of death,
hysterectomy, or arterial embolization to control bleeding. The end of bleeding was defined as the
time of the final recordedmeasurement of blood loss or the time of the last obstetric intervention to
stop bleeding.
In the Netherlands, uterine or internal iliac artery embolization is performed before resorting to
hysterectomy, if the woman’s hemodynamic condition is stable enough to perform this procedure.
During our study, 83.6% of the hospitals had this treatment modality available 24 hours per day, 7
days per week, and 92.5% of our study population gave birth in 1 of these hospitals. If a hospital does
not have this treatmentmodality available, it is common practice to transfer thewomanwith PPH to
a nearby hospital with embolization facilities. Embolization has almost completely substituted
ligation of uterine or internal iliac arteries in the Netherlands, and in our study, ligation of arteries was
performed in 0.8% of womenwith persistent PPH.
Statistical Analysis
Womenwith more severe PPH are more likely to receive early plasma transfusion, which confounds
the association of early plasma transfusion with maternal outcomes. We used time-dependent
propensity score matching to ensure that the contrasted groups were similar in terms of severity of
hemorrhage and other treatments for PPH.26-31 First, we calculated the predicted probability to
receive early plasma transfusion for all women in the cohort. Second, we selected pairs of women
with the same probability for receiving plasma transfusion. These pairs consisted of one womanwho
received early plasma transfusion and another womanwho did not. Third, we compared the
matched groups.
Propensity Scores
The propensity score reflects the estimated probability of initiation of plasma transfusion in women
with persistent PPH, given the observed characteristics of the women at the time of initiation of
plasma transfusion.28,29 We calculated a propensity score for every womanwith persistent PPH by
using a multivariable Cox proportional hazards model. The outcome variable in this model was time
to plasma transfusion, and the linear predictor at any givenminute from diagnosing persistent PPH
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was used as the propensity score. In womenwith initiation of plasma transfusion before diagnosing
persistent PPH (ie, women with placental abruption), we considered the time of diagnosing
persistent PPH as the time of initiating plasma transfusion.
We included baseline and time-dependent covariates associated with initiation of plasma
transfusion andmaternal outcome in a Coxmodel to calculate propensity scores. Selection of these
potentially confounding variables was based on clinical reasoning and prior knowledge.7,8,32-36 The
baseline covariates were mode of birth (ie, vaginal or cesarean), cause of hemorrhage (ie, uterine
atony, retained placenta, abnormally invasive placenta, or other), preeclampsia (yes or no), and
volume of crystalloids and colloids for fluid resuscitation (continuous variable). We included the
following time-dependent variables: estimated volume of blood loss (continuous variable), bleeding
rate (continuous variable), hemorrhagic shock (yes or no), oxytocin infusion (yes or no), misoprostol
(yes or no), ergometrine (yes or no), the prostaglandin E2 analogue sulprostone (yes or no), manual
removal of placenta (yes or no), exploration of uterine cavity and genital tract with anesthesia (yes
or no), intrauterine balloon tamponade (yes or no), tranexamic acid (yes or no), fibrinogen
concentrate (yes or no), recombinant factor VIIa (yes or no), packed RBCs transfusion (categorized
as 0, 1, 2, 3, or4 units), and platelet transfusion (yes or no). Additional information on handling of
the time-dependent covariates in statistical analyses is provided in eTable 2 in the Supplement.
Matching
We applied a 1:1 nearest-neighbor risk-set matching algorithm on the propensity score without
replacement, with a maximum caliper width of 0.1 of the SD of the logit of the propensity score.37-40
In this way, we sequentiallymatched everywomanwith persistent PPH inwhomplasma transfusion
was initiated at any given time point (0-60 minutes after diagnosis of persistent PPH) to a woman
with similar propensity score in whom plasma transfusion was not initiated before or at that same
time point (Figure 1). In this matched counterpart, plasma transfusion may have been initiated at a
later time during PPH. After cessation of PPH or after reaching an endpoint (ie, arterial embolization,
hysterectomy, or death), a womanwas no longer considered at risk for plasma transfusion for
correction of coagulopathy during ongoing hemorrhage.
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Propensity score is the probability of plasma transfusion at a specific time point, given the woman’s observed characteristics at that time point.
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Missing covariate data were imputed by using multiple imputation.41-43 We included all
confounding variables, outcome variables, and parameters associated with themissing variables as
predictive variables in the imputationmodels and generated 10 imputed data sets.We tested our Cox
model for nonproportional hazards by adding interactions with time.
In each imputed data set, we estimated the propensity score for initiation of plasma transfusion
for each woman with persistent PPH. We performed a time-dependent propensity score matching
within each of these imputed data sets, and then we pooled the effect estimates by averaging them
according to the Rubin’s rule.44-46
After matching, we performed a check of the balance between the confounding variables to
ensure our propensity score model was specified correctly. To this end, we calculated the
standardized differences in the confounding variables between the womenwith plasma transfusion
during the first 60minutes of persistent PPH and thewomenwith no or later plasma transfusion in
ourmatched cohort.47-50 Absolute standardized differences less than 10%are generally considered a
good balance of the observed confounding variables.28,51,52
Main and Sensitivity Analyses
We used logistic regression to assess the adjusted association of plasma transfusion during the first
60 minutes of persistent PPH with adverse maternal outcomes; the composite maternal outcome
was the dependent variable, and time of plasma transfusion (ie, early vs no or later transfusion) was
the independent variable. We used robust SEs to calculate 95% CIs.
We performed several sensitivity analyses to assess the robustness of our results and to assess
whether our effect estimate was influenced by women with plasma at a later time point in our
comparison group. First, we performed sensitivity analyses with initiation of plasma transfusion
during the first 120 and 180minutes of persistent PPH because a potential beneficial effect of
correction of coagulopathy has been previously described within the first 3 hours after the onset of
hemorrhage in obstetric and nonobstetric populations.24,25
Second, we performed sensitivity analyses by excluding pairs of womenwith a crossover of the
woman initially without plasma to treatment with plasma shortly after matching. These analyses
were performedwith a restriction of 15, 30, 45, and 60minutes on the time interval of switching
from no plasma to plasma treatment. For example, if a woman treated with plasma at 50minutes
was matched to a womenwithout plasma until 50minutes but with initiation of plasma at 64
minutes, we excluded this pair in the sensitivity analysis for no crossover within 15 minutes.
Third, we performed sensitivity analyses by excluding pairs of women with a crossover of the
woman initially without plasma to treatment with plasma while still being within the first 60minutes
of persistent PPH. For example, if a woman treated with plasma at 30minutes was matched to a
womanwithout plasma at 30minutes but with initiation of plasma at 55minutes, we excluded the
pair from this sensitivity analysis.
Results
Population
The cohort included 1391 womenwith PPHwho received 4 or more units of packed RBCs or a
multicomponent blood transfusion within 24 hours after birth (Figure 2). Of these women, we
classified 1260 (90.6%) as having persistent PPH.We excluded 43 womenwith persistent PPH
because of unknown time of initiation of plasma transfusion and 1 woman in whom plasma
transfusion had been started before birth because of leukemia instead of obstetric hemorrhage. Our
final cohort included 1216 women (mean [SD] age, 31.6 [5.0] years). Seven women (0.6%) died
because of PPH, 62 women (5.1%) had a hysterectomy, and 159 women (13.1%) had arterial
embolizations.
A total of 598women (49.2%) received plasma during ongoing PPH. Among women in the no
or later plasma transfusion group, 618 women (57.1%) did not receive plasma and 465 women
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(42.9%) received plasma at a later time after matching. Median (interquartile range [IQR]) time to
initiation of plasma transfusion was 105 (65-196) minutes. Overall, plasma transfusion was initiated
during the first 60 minutes of persistent PPH in 133 women (10.9%), during the first 120 minutes in
338 women (27.8%), and during the first 180minutes in 433 women (35.6%).
Baseline and time-dependent characteristics of womenwith early plasma transfusion vs no or
later plasma transfusion are presented in Table 1. We imputed missing data on volume of fluid
resuscitation (16.0%) and hemorrhagic shock at moment of diagnosing persistent PPH (34.9%). For
this latter time-dependent confounding variable, more data (ie, measured blood pressures and heart
rates) became available for an increasing proportion of women with progression of the PPH. An
adverse maternal outcomewas observed in 30women (22.6%) with plasma transfusion during the
first 60 minutes of persistent PPH and in 175 women (16.2%) with no or later plasma transfusions
(odds ratio, 1.51; 95% CI, 0.98-2.34) (Table 2).
Time-Dependent Propensity Score–Matched Population
The number of matched pairs of womenwith plasma transfusion during the first 60minutes and
womenwith no or later plasma transfusion fluctuated across the 10 imputed data sets. We found a
pooled average of 114 matches of women with plasma transfusion during the first 60 minutes and
womenwith no plasma or plasma transfusion at a later time during persistent PPH. Nineteen women
with plasma transfusion during the first 60minutes had nomatch on propensity score (Table 1).
Median (IQR) time to plasma transfusion in womenwith plasma transfusion during the first 60
minutes was 40 (16-50) minutes. Of their matched counterparts, 47 women (41.2%) did not receive
plasma during PPH and 67women (58.8%) received plasma at a later time during PPH,with amedian
(IQR) time to plasma transfusion of 66 (47-90) minutes in these 67 women. Across the 10 imputed
data sets, we included a pooled average of 29 women twice in this matched cohort: first as a woman
Figure 2. Derivation of Study Population
131 Women excluded
36 With successful initial treatment
95 With missing time of first-line therapy
44 Women excluded
1 With plasma transfusion prior to hemorrhage
43 With missing initiation time of plasma transfusion
1391 Women with PPH who received transfusion ≥4 units packed RBCs 
or multicomponent blood transfusion from 2011 to 2013
1260 Women with persistent PPH refractory to first-line therapy to control bleeding
1216 Women with persistent PPH included
133 With plasma within 60 min
Median (IQR) time to plasma, 40 (16-50) min
Median (IQR) RBC, 5 (4-8) units




With no or later plasma
With later plasma transfusion
Median (IQR) RBC, 4 (3-5) units
With no plasma transfusion
Median (IQR) time to plasma, 135 (92-219) min
Median (IQR) FFP, 0 (0-2) units
114 Received early plasma
Median (IQR) time to plasma, 40 (23-50) min
Median (IQR) RBC, 4 (3-7) units




Received no or later plasma
With later plasma transfusion
Median (IQR) RBC, 4 (4-6) units
With no plasma transfusion
Median (IQR) time to plasma, 66 (47-90) min
Median (IQR) FFP, 2 (2-4) units
Matching
FFP indicates fresh frozen plasma; IQR, interquartile
range; PPH, postpartum hemorrhage; and RBC, red
blood cell.
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Table 1. Characteristics ofWomenWith Persistent PPH in the Total Cohort and the Propensity Score–Matched
Cohort Stratified by Plasma Transfusion Strategy
Characteristic
Overall Cohort
at Moment of Diagnosing
Persistent PPH
Propensity Score–Matched
Cohort at Moment of Matching
























Vaginal 846 (78.1) 86 (64.7) 82 (72.0) 76 (66.7)
2.9
Cesarean 231 (21.3) 47 (35.3) 32 (28.0) 38 (33.3)
Unknown 6 (0.6) 0 NA NA
Cause
of hemorrhaged
Uterine atony 701 (64.7) 79 (59.4) 70 (60.9) 69 (60.8) [Reference]
Retained placenta 188 (17.4) 24 (18.0) 24 (20.9) 20 (17.4) 0.8
Abnormally
invasive placenta
93 (8.6) 12 (9.0) 7 (6.3) 11 (9.6) 0.6
Othere 101 (9.3) 18 (13.5) 14 (11.9) 14 (12.2) 5.4





≤2 266 (24.6) 32 (24.1) 27 (23.7) 33 (28.8)
>2 to ≤4 438 (40.4) 46 (34.6) 61 (53.2) 55 (48.5)
>4 211 (19.5) 29 (21.8) 26 (23.1) 26 (22.7)
Unknown 168 (15.5) 26 (19.5) NA NA
Volume
of blood loss, Lf
≤1 605 (55.9) 43 (32.3) 8 (7.4) 2 (1.8)
1.6>1 to ≤2 349 (32.2) 45 (33.8) 34 (29.5) 35 (30.3)
>2 129 (11.9) 45 (33.8) 72 (63.1) 78 (68.0)
Bleeding rate, L/hf
≤1 576 (53.2) 64 (48.1) 57 (49.8) 44 (38.4)
4.0>1 to ≤2 231 (21.3) 33 (24.8) 33 (28.5) 44 (38.3)
>2 276 (25.5) 36 (27.1) 25 (21.6) 27 (23.3)
Hemorrhagic shock
No 378 (34.9) 56 (42.1) 47 (41.5) 59 (51.4)
9.5
Yes 303 (28.0) 55 (41.4) 67 (58.5) 56 (48.6)
Unknown 402 (37.1) 22 (16.5) NA NA
Obstetric
interventions
Oxytocin infusion 422 (39.0) 34 (25.6) 45 (39.1) 53 (46.1) 1.3
Misoprostol 153 (14.1) 12 (9.0) 21 (18.7) 19 (16.6) 6.9
Ergometrine 23 (2.1) 1 (0.8) 11 (9.5) 4 (3.4) 2.6
Sulprostone 59 (5.4) 35 (26.3) 62 (54.3) 60 (52.5) 5.1
Manual removal
of placenta








8 (0.7) 1 (0.8) 18 (15.3) 21 (18.2) 3.2
(continued)
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Table 1. Characteristics ofWomenWith Persistent PPH in the Total Cohort and the Propensity Score–Matched
Cohort Stratified by Plasma Transfusion Strategy (continued)
Characteristic
Overall Cohort
at Moment of Diagnosing
Persistent PPH
Propensity Score–Matched
Cohort at Moment of Matching

























Tranexamic acid 19 (1.8) 17 (12.8) 39 (34.1) 39 (33.8) 2.0
Fibrinogen
concentrate





0 1050 (97.0) 97 (72.9) 25 (21.9) 26 (22.8) [Reference]
1 14 (1.3) 12 (9.0) 20 (17.8) 23 (20.1) 5.8
2 11 (1.0) 13 (9.8) 41 (35.8) 36 (31.2) 5.1
3 4 (0.4) 3 (2.3) 14 (12.5) 19 (16.5) 4.6
≥4 4 (0.4) 8 (6.0) 14 (12.0) 11 (9.5) 9.4
≥1 Unit
of platelets
2 (0.2) 4 (3.0) 2 (1.5) 4 (3.5) 0.7
Abbreviations: NA, not applicable; PPH, postpartum
hemorrhage.
a Includes womenwith no FFP transfusion andwomen
with FFP transfusion at a later time during PPH.
b The proportion of womenwho have undergone a
time-dependent intervention increases during the
course of PPH, as an increasing amount of
interventions will be performed in a single woman
until cessation of the hemorrhage.
c Numbers of women and percentages are means
derived from 10 imputed databases, and numbers of
womenwere rounded to the nearest integer.
Therefore, theymay exceed the total number of
women or a proportion of 1, and the same number of
womenmay correspond to different proportions.
d Covariate entered as a categorical variable in the
propensity score model.
e Includes genital tract trauma, placenta previa,
placental abruption, and congenital or acquired
coagulation disorders.
f Covariate entered as a continuous variable in the
propensity score model.
g Recombinant factor VIIa was not given to anywoman
prior to diagnosing persistent PPH or matching.
Table 2. Outcomes ofWomenWith Persistent PPH in the Total Cohort and the Propensity Score–Matched Cohort Stratified by Plasma Transfusion Strategy
Outcome















Plasma Within 60 min
Composite 175/1083 (16.2) 30/133 (22.6) 1.51 (0.98-2.34) 23/114 (19.9) 24/114 (21.2) 1.09 (0.57-2.09)
Mortality 5/1083 (0.5) 2/133 (1.5) 2/114 (1.3) 2/114 (1.8)
Hysterectomy 50/1083 (4.6) 12/133 (9.0) 10/114 (8.3) 10/114 (8.9)
Arterial
embolization
137/1083 (12.7) 22/133 (16.5) 16/114 (13.9) 18/114 (15.8)
Plasma Within 120 min
Composite 128/878 (14.6) 77/338 (22.8) 1.73 (1.26-2.37) 59/283 (21.0) 59/283 (21.0) 1.00 (0.67-1.51)
Mortality 3/878 (0.3) 4/338 (1.2) 2/283 (0.8) 4/283 (1.4)
Hysterectomy 37/878 (4.2) 25/338 (7.4) 19/283 (6.7) 20/283 (7.2)
Arterial
embolization
99/878 (11.3) 60/338 (17.8) 47/283 (16.5) 45/283 (15.9)
Plasma Within 180 min
Composite 95/783 (12.1) 110/433 (25.4) 2.47 (1.82-3.35) 80/348 (23.0) 77/348 (22.2) 0.96 (0.67-1.37)
Mortality 3/783 (0.4) 4/433 (0.9) 4/348 (1.0) 4/348 (1.1)
Hysterectomy 28/783 (3.6) 34/433 (7.9) 23/348 (6.5) 27/348 (7.7)
Arterial
embolization
73/783 (9.3) 86/433 (19.9) 64/348 (18.5) 58/348 (16.6)
Abbrevations: OR, odds ratio; PPH, postpartum hemorrhage.
a Adjusted for all variables included in the propensity score.
b Includes womenwithout plasma transfusion and womenwith plasma transfusion at a
later time during PPH.
c Numbers of women and percentages are pooled averages derived from 10 imputed
databases, and numbers of womenwere rounded to the nearest integer. Therefore,
theymay exceed the total number of women or a proportion of 1, and the same
number of womenmay correspond to different proportions.
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with no or later plasma transfusion and later as a womanwith plasma transfusion during the first
60minutes.
Outcomes in Adjusted Analyses
The distribution of baseline and time-dependent covariates in thematched cohort were well
balanced between womenwith plasma transfusion during the first 60minutes and womenwith no
or later plasma transfusion (Figure 3 and Table 2). In the matched cohort, we observed a pooled
average of 24 adverse maternal outcomes (21.2%) in womenwith plasma transfusion within 60
minutes vs 23 adverse maternal outcomes (19.9%) in womenwith no or later plasma transfusion
(odds ratio, 1.09; 95% CI, 0.57-2.09).
Sensitivity Analyses
Unadjusted and adjusted sensitivity analyses in womenwith plasma transfusion within 120minutes
and within 180minutes vs no or later plasma transfusion within these intervals yielded similar results
as the primary analysis (Table 2) (eTable 3 and eTable 4 in the Supplement). In the sensitivity analyses
excluding pairs of women in which a woman crossed over from no or later plasma to plasma
transfusion 15, 30, 45, or 60minutes after matching, we also found effect estimates comparable to
our main analysis (eTable 5 in the Supplement). In the sensitivity analysis excluding 29 pairs of
women because of crossover from no or later plasma to plasma transfusion during the first 60
minutes of persistent PPH, the odds ratio was 0.94 (95% CI, 0.43-2.06) for the remaining pairs
of women.
Figure 3. Balance of Covariate Values After Time-Dependent Propensity ScoreMatching ofWomen
With Persistent PostpartumHemorrhage
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Discussion
In this multicenter, time-dependent propensity score–matched cohort study of womenwith
persistent PPH, empirical, early plasma transfusion was not associated with better maternal
outcomes compared with womenwho received no or later plasma transfusion. Similar results were
observed in all sensitivity analyses.
Early plasma transfusion is believed to improvematernal outcomes because it could prevent or
treat coagulopathy occurring amongwomen treated for persistent PPH. Studies evaluating the effect
of plasma transfusion on outcomes of womenwith severe PPH are scarce, to our knowledge.
Contrary to our findings, a single-center observational study15 among 142 women with severe PPH
reported a decreased rate of advanced interventions associated with a high ratio of plasma to packed
RBCs. In that study, only 41 women received plasma in themanagement of PPH. Similarly, high ratios
of plasma to packed RBCs have been reported to improvematernal outcomes when incorporated
within PPH protocols, but whether this improvement could be attributed to the transfusion strategy
or to other parts of the protocol is unclear.17,18
The observed absence of an effect of early plasma transfusion onmaternal outcomes among
womenwith persistent PPHmay have several explanations. First, there may have been too few
womenwho developed significant coagulopathy and therefore there was no need to treat or prevent
it. This explanation is consistent with findings from studies amongwomenwith severe PPH inwhom
fibrinogen concentrate was administered early during hemorrhage to prevent and correct
coagulopathy.53,54 In these studies, most women had not developed coagulopathy at the time of
administration of fibrinogen, and outcomes did not improve. Yet, in the TeMpOH-1 study cohort,21
26% of women eventually reached a fibrinogen level of less than 200mg/dL (to convert to
micromoles per liter, multiply by 0.0294), and 5% of women reached this level after losing less than
2 L of blood,55 which suggests that the absence of coagulopathy in our cohort is not an explanation
for our findings.
Second, plasmamight not be effective in preventing or treating coagulopathy in women with
persistent PPH, or the dose of plasmamay have been too low to show a difference. It is conceivable
that personalized supplementation of factor concentrates would be a better strategy to prevent
adverse outcomes among womenwith PPH.
Third, 42.9% of the women in the control group were eventually also treated with plasma.
Some of these women received plasma relatively shortly after themoment at which they had been
matched to their rapidly treated counterpart. If such later plasma was as effective as early
administration of plasma, that could explain the observed absence of association of early plasma
transfusion with outcomes. Yet, sensitivity analysis amongmatched pairs without this problem
showed similar results, suggesting that this also did not explain our findings.
Limitations and Strengths
Our findings had some limitations and should be interpreted with caution, as theymay also be
explained by residual confounding. Womenwith more severe PPH are more likely to be rapidly
treated with plasma than womenwith less severe hemorrhages. Time-dependent propensity score
matching permitted us to balance all measured prognostic factors at any time during PPH, but this
technique does not account for the distribution of unknown or unmeasured confounders. Yet, the
professionals treating the women with severe PPH in our cohort carefully documented all
parameters that are generally considered relevant with respect to the severity and treatment of PPH,
to our knowledge. We could not think of any other parameters that might explain the observed
absence of association. In addition, our findings may also be explained by random error. The
confidence interval around the point estimate included values between 0.57 and 2.09, suggesting
that there may be a protective or harmful association of early plasma transfusion with maternal
outcomes, in line with the findings of previous studies.15-20
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A strength of our study was the use of persistent PPH, an intuitive and pragmatic definition of
severe PPH with easy translation to daily clinical practice, to select women for this analysis.8,22,36 In
the Netherlands, clinical parameters and the times of interventions are carefully recorded during
obstetric emergencies. Thus, we were able to make a detailed reconstruction of the course of PPH,
andwe had no loss to follow up. In addition, extensive sensitivity analyses showed consistent results.
Conclusions
This cohort study found that among womenwith persistent PPH, empirical early plasma transfusion
was not associated withmaternal deaths, hysterectomies, or arterial embolizations comparedwith
no or later plasma transfusion. Results were carefully adjusted for severity of PPH and time-
dependent confounding, but residual confounding cannot be ruled out because of the observational
nature of the study design.
Our findings do not suggest that plasma transfusion has no place in the treatment of women
with severe PPH. Rather, our study underlines the importance of developing tools to diagnose
coagulopathy during persistent PPH. These tools may enable individualization of treatment of
womenwith persistent PPH by identifyingwomenwho develop coagulopathy during persistent PPH.
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